Log in

NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

$1.84
+0.01 (+0.55 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$1.81
Now: $1.84
$1.88
50-Day Range
$1.46
MA: $1.81
$2.46
52-Week Range
$1.43
Now: $1.84
$5.69
Volume240,430 shs
Average Volume323,857 shs
Market Capitalization$99.75 million
P/E Ratio5.94
Dividend YieldN/A
Beta0.71
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.03 million
Cash Flow$0.86 per share
Book Value$2.42 per share

Profitability

Net Income$31.85 million

Miscellaneous

Employees106
Market Cap$99.75 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.


Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.07. The biotechnology company earned $5.68 million during the quarter, compared to the consensus estimate of $5.06 million. Strongbridge Biopharma had a return on equity of 45.77% and a net margin of 211.37%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$18-20 million, compared to the consensus revenue estimate of $$20.82 million.

What price target have analysts set for SBBP?

6 analysts have issued 1 year price objectives for Strongbridge Biopharma's shares. Their forecasts range from $8.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $12.80 in the next year. This suggests a possible upside of 595.7% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

What is the consensus analysts' recommendation for Strongbridge Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

Headlines about SBBP stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Strongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 844,200 shares, an increase of 10.5% from the November 14th total of 763,800 shares. Based on an average daily trading volume, of 350,100 shares, the days-to-cover ratio is currently 2.4 days. Approximately 2.5% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.17%), Point72 Asset Management L.P. (0.88%), Essex Investment Management Co. LLC (0.77%), Millennium Management LLC (0.45%) and Barclays PLC (0.04%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Essex Investment Management Co. LLC and Barclays PLC. View Insider Buying and Selling for Strongbridge Biopharma.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and State Street Corp. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $1.84.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $99.75 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  573
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel